TL;DR: The Centers for Medicare & Medicaid Services modified NCD 231 governing non-implantable pelvic floor electrical stimulators, effective January 9, 2026. Here's what changes for billing teams.
This CMS pelvic floor stimulator coverage policy update affects DME suppliers and urology, urogynecology, and physical therapy billing teams who submit claims for home-use pelvic floor electrical stimulation devices. NCD 231 in the Medicare system sets the national coverage floor for these devices — and the criteria are specific. Get them wrong, and you're looking at claim denial. This post covers exactly what the policy requires, who qualifies, and what your billing team should do right now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Medicare) |
| Policy | Non-Implantable Pelvic Floor Electrical Stimulator |
| Policy Code | NCD 231 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Medium |
| Specialties Affected | Urology, Urogynecology, Physical Therapy, DME Suppliers |
| Key Action | Confirm documented PME trial failure before submitting claims for pelvic floor stimulator coverage |
CMS Pelvic Floor Electrical Stimulator Coverage Criteria and Medical Necessity Requirements 2026
The coverage policy under NCD 231 is narrow. CMS covers pelvic floor electrical stimulation with a non-implantable stimulator for one specific use: treating stress urinary incontinence, urge urinary incontinence, or a combination of both.
That sounds straightforward. It isn't — because two hard gates determine whether a claim will pay.
Gate one: Cognitive status. The patient must be cognitively intact. CMS doesn't define a specific assessment tool here, but the intent is clear. If there's documented cognitive impairment in the chart, this device isn't covered. Your billing team should flag this during pre-authorization review.
Gate two: Failed PME trial. This is where most claims fall apart. The patient must have a documented, failed trial of pelvic muscle exercise (PME) training before the stimulator is covered. "Failed" has a precise definition here — no clinically significant improvement in urinary continence after completing four weeks of an ordered PME plan. That plan must be designed to increase periurethral muscle strength.
Four weeks. Ordered plan. No clinically significant improvement. All three elements must be documented in the chart before you bill for the device.
This is the medical necessity standard CMS applies under NCD 231. If the documentation doesn't show all three, you don't have a covered claim — you have a denial waiting to happen. Talk to your compliance officer if your ordering physicians aren't currently documenting PME outcomes in a way that maps to this definition.
What Counts as a "Failed" PME Trial?
This matters for reimbursement, so be precise. The four-week clock starts when the ordered plan begins — not when the patient reports symptoms. The plan must be designed to increase periurethral muscle strength specifically, not just general pelvic floor awareness or biofeedback without exercise.
"No clinically significant improvement" is subjective, and CMS doesn't quantify it. That's a problem. Your providers need to document baseline voiding frequency, leakage episodes, or pad use — then document the same metrics at the four-week mark. Without before-and-after data, the failed trial claim is unsupportable.
This is a documentation gap that kills clean claims. Fix it before January 9, 2026.
Prior Authorization Under NCD 231
The Centers for Medicare & Medicaid Services does not specify a prior authorization requirement in the NCD 231 coverage policy itself. However, your Medicare Administrative Contractor may apply local coverage determination requirements on top of this national policy. Check with your MAC before assuming prior auth isn't required. Some MACs have issued LCDs for pelvic floor stimulators that add documentation or prior auth steps beyond what NCD 231 requires.
Don't skip that check. MAC-level requirements vary by region, and a clean NCD doesn't mean your MAC won't flag the claim.
CMS Pelvic Floor Electrical Stimulator Exclusions and Non-Covered Indications
NCD 231 doesn't cover pelvic floor electrical stimulation for every patient with urinary incontinence. The exclusions aren't a long list — but they're firm.
Patients who are not cognitively intact are not covered. Full stop. The policy explicitly limits coverage to cognitively intact patients. If dementia, delirium, or another condition affects the patient's ability to participate in and benefit from the treatment, the device falls outside covered use.
Patients who have not completed a documented PME trial are not covered. This isn't just a documentation issue — it's a sequencing issue. The PME trial must happen first. Billing for the stimulator before the four-week trial period is complete puts you in non-covered territory, regardless of what the physician believes about the patient's likelihood of response.
Indications beyond stress and urge urinary incontinence are not addressed. Some clinicians use pelvic floor stimulation for fecal incontinence, pelvic pain, or interstitial cystitis. NCD 231 covers only urinary incontinence — specifically stress and urge types. Anything else is outside the scope of this coverage policy. That doesn't mean it's never reimbursable, but it won't be covered under NCD 231.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Stress urinary incontinence — cognitively intact patient, failed 4-week PME trial | Covered | Not specified in NCD 231 | Requires documented PME trial with pre/post outcomes |
| Urge urinary incontinence — cognitively intact patient, failed 4-week PME trial | Covered | Not specified in NCD 231 | Requires documented PME trial with pre/post outcomes |
| Mixed stress and urge urinary incontinence — cognitively intact patient, failed 4-week PME trial | Covered | Not specified in NCD 231 | Requires documented PME trial with pre/post outcomes |
| Urinary incontinence in cognitively impaired patient | Not Covered | — | Cognitive intactness is a hard eligibility requirement |
| Urinary incontinence without documented failed PME trial | Not Covered | — | PME trial completion and failure must precede device coverage |
| Fecal incontinence, pelvic pain, or other non-urinary indications | Not Addressed / Not Covered under NCD 231 | — | Outside scope of NCD 231; check other NCDs or LCDs |
CMS Pelvic Floor Electrical Stimulator Billing Guidelines and Action Items 2026
The effective date of this update is January 9, 2026. That gives your billing team a defined window to get processes in order. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Audit your PME documentation templates before January 9, 2026. The four-week PME trial must be an ordered plan, not informal coaching or patient-initiated exercise. If your ordering providers are documenting "encouraged Kegel exercises" rather than a prescribed, structured program, that won't satisfy NCD 231. Work with your clinical informatics or EHR team to build a PME trial template that captures start date, exercise protocol, and four-week outcome data. |
| 2 | Add cognitive status screening to your pre-billing checklist. The coverage policy requires cognitive intactness but doesn't specify a tool. Pick one — MMSE, MoCA, or a documented clinical notation — and make it a required field before a pelvic floor stimulator order moves to billing. If the chart doesn't document cognitive status, kick it back to the provider before claim submission. |
| 3 | Check your MAC's local coverage determination for additional requirements. NCD 231 sets the floor. Your Medicare Administrative Contractor may have issued an LCD with additional documentation, prior authorization, or clinical criteria. Pull your MAC's LCD for pelvic floor stimulators now and compare it against NCD 231. Where they conflict, the more restrictive policy governs your claims. |
| 4 | Train your DME suppliers on the PME failure definition. If you work with external DME suppliers who drop-ship these devices, they need to understand the NCD 231 criteria as well as your billing team does. A supplier who ships a device based on a physician order without confirming PME documentation exposes you to claim denial and potential recoupment. Send them this policy summary and the specific four-week definition. |
| 5 | Set up a pre-submission documentation review for these claims. Pelvic floor electrical stimulation billing involves a coverage policy with two hard prerequisites — cognitive status and failed PME trial. Both need to be confirmed before the claim goes out. Build a two-point check into your claim submission workflow. This takes five minutes per claim and prevents months of appeals work. |
| 6 | If your practice bills for both the device and associated office visits, reconcile medical necessity documentation across both claim types. The notes supporting the device claim need to align with visit notes. Inconsistency between claim types is a red flag for post-payment review. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Pelvic Floor Electrical Stimulation Under NCD 231
Covered Codes
The NCD 231 policy document does not list specific CPT or HCPCS codes. This is a known gap in the CMS published policy. Pelvic floor electrical stimulation billing typically involves HCPCS codes for DME and the associated devices — your MAC's LCD is the authoritative source for which codes apply in your region.
Do not guess at codes based on general DME billing knowledge. Pull your MAC's LCD for pelvic floor stimulators, which will list the specific HCPCS codes that align with NCD 231 coverage. Submit only the codes your MAC has validated for this indication.
A Note on Code Assignment
Because NCD 231 doesn't enumerate covered codes, your coding team needs to work from the MAC LCD that corresponds to your region. The absence of codes in the NCD is not unusual for older national coverage determinations — CMS often leaves code-level specificity to the MAC level. But it does mean that pelvic floor stimulator billing guidelines at the claim level will vary by contractor.
If you're unsure which HCPCS codes apply to your claims under NCD 231, contact your MAC directly or loop in your billing consultant before the January 9, 2026 effective date.
What This Policy Change Actually Means for Your Revenue Cycle
Here's the honest take: the NCD 231 modification doesn't dramatically expand or restrict coverage. The core criteria — stress and urge urinary incontinence, cognitive intactness, failed PME trial — have been the framework for this coverage area for years.
What changes matter here is that CMS has revisited and reissued this policy as of January 9, 2026. That's a signal to audit your current documentation practices against the stated criteria — not assume your existing workflow already captures everything.
The real exposure is the PME trial documentation. Most billing teams assume the physician has documented it. Most physicians assume "four sessions of pelvic floor PT" counts. It doesn't if it wasn't an ordered plan designed to increase periurethral muscle strength, tracked over four weeks with outcome data. That gap is where claim denial happens — and where post-payment audits find money to recoup.
Fix the documentation template. Confirm MAC requirements. Brief your DME partners. That's the work.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.